The Association of British HealthTech Industries (ABHI) US Accelerator has received a record number of applications for its 2022 cohort, and has therefore expanded its offer to welcome more companies into the programme.
Initially, ABHI had planned to accept 30 companies into the cohort, but due to incredibly high interest, they have expanded intake to 40 places, which includes a diverse mix of medical device, diagnostics and digital health businesses, several of which are long-standing members of the programme, and a host of new entrants.
With the programme starting in January, the ABHI US Accelerator supports UK HealthTech companies looking enter and upscale in the US healthcare market. Over the next 12 months, ABHI will work with the companies to provide bespoke support in identifying and filling need gaps, and setting individual goals to support company growth. Companies will also be boosted by access to an expansive network of in-market experts.
Paul Benton, Managing Director, International, said: “Since its establishment in 2017, the ABHI US Accelerator has led to multiple international research collaborations and new business generated for UK industry. Offering nationwide support, and drawing on the relationships and connections built up across the US, we are particularly excited by how the programme has expanded, and with international travel now resuming, we are confident 2022 will deliver a fantastic return on investment for participating companies.”
Businesses on the programme will enjoy exclusive week-long trade missions to the US, providing them with prime opportunities to engage with key stakeholders for their individual company objectives. These missions will see a series of meetings with senior leaders, clinicians and procurement teams from world class hospital systems, giving them the opportunity to present proven UK HealthTech to new clients.
The Global Business Development Director for X-Lab, which is a participant of the programme, Steve Box said “Through the US Accelerator contacts, we were connected to a scale-out programme in LA, where we were able to find a great consultant who has actually now become our VP of US Business Development, and we now have a verbal agreement for two US laboratory organisations to be our pilot sites in the US.”
Places for 2022 cohort of the ABHI US Accelerator are closed, but the waiting list for the 2023 intake is now open. For more information, and to discuss the opportunity, contact lottie.mcmahon@abhi.org.uk.
